Physician profile
Birgit A Arb
NPI 1669466405
$1,786.10
in general payments reported to CMS, 2019-2025
33 companies · $951 in 2025
The $951 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $26.11 · 2021: $11.92 · 2022: $213 · 2023: $174 · 2024: $410 · 2025: $951.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,505 · Education: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,504.50 |
| Education | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $198.00 | 2022 | |
| Abbvie INC. | $175.03 | 2023-2025 | Venclexta |
| Celgene Corporation | $118.18 | 2023-2025 | Reblozyl, Pomalyst, Opdualag |
| Novartis Pharmaceuticals Corporation | $98.87 | 2024-2025 | |
| Pfizer INC. | $97.69 | 2024-2025 | |
| E.R. Squibb & Sons, L.L.C. | $82.59 | 2020-2025 | Opdivo, Opdualag |
| Genentech USA, INC. | $80.06 | 2023-2025 | Polivy, Itovebi, Venclexta |
| Astrazeneca Pharmaceuticals LP | $76.05 | 2023-2025 | Lynparza, Enhertu |
| Accord Healthcare, INC. | $73.47 | 2025 | |
| Incyte Corporation | $68.46 | 2024-2025 | Monjuvi, Jakafi, Zynyz |
| Daiichi Sankyo INC. | $67.24 | 2023-2025 | Enhertu, Datroway |
| Exelixis INC. | $54.87 | 2024-2025 | Cabometyx |
| Merck Sharp & Dohme LLC | $51.66 | 2025 | Keytruda, Keytruda Qlex |
| Servier Pharmaceuticals LLC | $46.54 | 2025 | |
| Gilead Sciences, INC. | $45.28 | 2021-2024 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $40.33 | 2024 | Ojjaara |
| Takeda Pharmaceuticals U.S.A., INC. | $37.32 | 2023-2025 | Iclusig, Alunbrig |
| Adc Therapeutics America, INC. | $34.11 | 2024-2025 | |
| Genmab U.S., INC. | $30.97 | 2024 | Tivdak |
| Astellas Pharma US INC | $30.37 | 2025 | Vyloy |
| Deciphera Pharmaceuticals INC. | $28.82 | 2025 | Romvimza, Qinlock |
| Beone Medicines USA, INC. | $28.19 | 2025 | Tevimbra |
| Pharmaessentia USA Corporation | $27.25 | 2025 | Besremi |
| Regeneron Healthcare Solutions, INC. | $25.59 | 2024 | Libtayo |
| Sobi, INC | $22.79 | 2024 | |
| Taiho Oncology, INC. | $22.78 | 2025 | |
| Eisai INC. | $22.69 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.20 | 2025 | |
| Janssen Biotech, INC. | $19.21 | 2025 | Talvey, Darzalex |
| Beigene USA, INC. | $16.30 | 2024 | Brukinsa |
| Jazz Pharmaceuticals INC. | $15.28 | 2024 | |
| Emd Serono, INC. | $14.92 | 2022 | |
| Novocure INC. | $12.99 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Birgit Arb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.